1
40
2
-
Text
A resource consisting primarily of words for reading. Examples include books, letters, dissertations, poems, newspapers, articles, archives of mailing lists. Note that facsimiles or images of texts are still of the genre Text.
URL Address
<a href="http://doi.org/10.1358/dof.2010.035.08.1520865" target="_blank" rel="noreferrer noopener">http://doi.org/10.1358/dof.2010.035.08.1520865</a>
Pages
635–642
Issue
8
Volume
35
Dublin Core
The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/.
Title
A name given to the resource
Farnesoid X receptor-Acting through bile acids to treat metabolic disorders.
Publisher
An entity responsible for making the resource available
Drugs of the future
Date
A point or period of time associated with an event in the lifecycle of the resource
2010
2010-08
Creator
An entity primarily responsible for making the resource
Zhang Yanqiao
Description
An account of the resource
Farnesoid X receptor (FXR) is a member of the nuclear receptor superfamily and plays an important role in maintaining bile acid, lipid and glucose homeostasis. Bile acids are endogenous ligands for FXR. However, bile acids may also activate pathways independent of FXR. The development of specific FXR agonists has provided important insights into the role of FXR in metabolism. Recent data have demonstrated that FXR is a therapeutic target for treatment of certain metabolic disorders. This review will focus on recent advances in the role of FXR in metabolic disease.
Identifier
An unambiguous reference to the resource within a given context
<a href="http://doi.org/10.1358/dof.2010.035.08.1520865" target="_blank" rel="noreferrer noopener">10.1358/dof.2010.035.08.1520865</a>
Rights
Information about rights held in and over the resource
Article information provided for research and reference use only. All rights are retained by the journal listed under publisher and/or the creator(s).
2010
Drugs of the future
Zhang Yanqiao
-
Text
A resource consisting primarily of words for reading. Examples include books, letters, dissertations, poems, newspapers, articles, archives of mailing lists. Note that facsimiles or images of texts are still of the genre Text.
URL Address
<a href="http://doi.org/10.1358/dof.2010.35.8.1520865" target="_blank" rel="noreferrer noopener">http://doi.org/10.1358/dof.2010.35.8.1520865</a>
Rights
Article information provided for research and reference use only. All rights are retained by the journal listed under publisher and/or the creator(s).
Pages
635-641
Issue
8
Volume
35
Search for Full-text
Locate full-text within NEOMED Library's e-journal collections
<p>Users with a NEOMED Library login can search for full-text journal articles at the following url: <a href="https://libraryguides.neomed.edu/home">https://libraryguides.neomed.edu/home</a></p>
Dublin Core
The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/.
Title
A name given to the resource
FARNESOID X RECEPTOR: ACTING THROUGH BILE ACIDS TO TREAT METABOLIC DISORDERS
Publisher
An entity responsible for making the resource available
Drugs of the Future
Date
A point or period of time associated with an event in the lifecycle of the resource
2010
2010-08
Subject
The topic of the resource
fatty liver-disease; foam-cell formation; growth-factor receptor; heterodimer partner; insulin-resistance; nonalcoholic steatohepatitis; orphan nuclear receptor; Pharmacology & Pharmacy; primary rat hepatocytes; protein-kinase-c; regulatory cascade; small
Creator
An entity primarily responsible for making the resource
Zhang Y
Description
An account of the resource
The famesoid X receptor (FXR) is a member of the nuclear receptor superfamily and plays an important role in maintaining bile acid, lipid and glucose homeostasis. Bile acids are endogenous ligands for FXR. However, bile acids may also activate pathways independent of FXR. The development of specific FXR agonists has provided important insights into the role of FXR in metabolism. Recent data have demonstrated that FXR is a therapeutic target for the treatment of certain metabolic disorders. This review will focus on recent advances in the role of FXR in metabolic disease.
Identifier
An unambiguous reference to the resource within a given context
<a href="http://doi.org/10.1358/dof.2010.35.8.1520865" target="_blank" rel="noreferrer noopener">10.1358/dof.2010.35.8.1520865</a>
Format
The file format, physical medium, or dimensions of the resource
Journal Article
2010
Drugs of the future
fatty liver-disease
foam-cell formation
growth-factor receptor
heterodimer partner
insulin-resistance
Journal Article
Nonalcoholic steatohepatitis
orphan nuclear receptor
Pharmacology & Pharmacy
primary rat hepatocytes
protein-kinase-c
regulatory cascade
Small
Zhang Y